ioflupane (123l)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for DaTSCAN. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DaTSCAN.

This EPAR was last updated on 10/02/2022

Authorisation details

Product details
Agency product number
Active substance
ioflupane (123l)
International non-proprietary name (INN) or common name
ioflupane (123l)
Therapeutic area (MeSH)
  • Tomography, Emission-Computed, Single-Photon
  • Lewy Body Disease
  • Parkinson Disease
  • Alzheimer Disease
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
GE Healthcare B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

GE Healthcare B.V.
De Rondom 8
5612 AP, Eindhoven 
The Netherlands

Product information

10/05/2021 DaTSCAN - EMEA/H/C/000266 - N/0061

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Diagnostic radiopharmaceuticals

Therapeutic indication

This medicinal product is for diagnostic use only.

DaTSCAN is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:

  • In adult patients with clinically uncertain Parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from Parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. DaTSCAN is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
  • In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. DaTSCAN is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia.

Assessment history

How useful was this page?

Add your rating
2 ratings
1 rating